A chamber of hope for hemophilia
Article Abstract:
One in five thousand males are affected by the X-linked bleeding disorder called Hemophilia. Therapeutic strategies for hemophilia have concentrated on how to replace defective or deficient proteins.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
A chamber of hope for hemophilia
Article Abstract:
Recombinant derived substitutes for Factors VIII and IX have been the focus of research on hemophilia, an X-linked bleeding disorder affecting approximately 1 in 5,000 males.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
In vivo bypass of hemophilia A coagulation defect by Factor XIIa implant
Article Abstract:
By administering recombinant Factor VIIa, you can bypass hemophilia A and B coagulation defects. Hemophilia A and B are caused by Factor VIII and Factor IX deficiencies.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The forecasting performance of implied volatility from live cattle options contracts: Implications for agribusiness risk management
- Abstracts: Staying ahead of the retail game. Kiosks - it's all about connectivity
- Abstracts: The MBA: managers only please. An asset in any field. A degree of effort
- Abstracts: Fidelity American Special Situations. Fidelity American
- Abstracts: New rules for gene patents. Genomics company formed from Framingham heart study. Inquiry into gene therapy widens